The Company

Jupiter Biomedical Research (JBR) was formed on December 29, 2016. The patents for the two product candidates were contributed by Dr. Tucker to the Company on December 30, 2016. On December 30, 2016, the Company also initiated a private placement. Over the next few months we will be expanding and enhancing our existing patents.

Introduction

JBR is an innovative drug development company holding patents for a potential brain cancer (glioblastoma multiforme) therapeutic (JBR-102) and for an antiviral treatment (JBR-201) intended for measles virus infection and associated diseases such as multiple sclerosis (MS) and subacute sclerosing panencephalitis (SSPE).  In the short term, the company’s focus will be on preclinical and clinical development of JBR-102 for the treatment of brain cancer and other epidermoid tumors.  The long-term strategic direction for both development candidates will encompass investigation of treatments for other solid tumor cancers (breast, lung, etc.), hematologic cancers and neurologic diseases caused by viruses.

Regarding its lead clinical candidate for brain cancer, the Company believes that it has accomplished sufficient preclinical animal testing and in vitro assessments to provide the regulatory required data on the safety and potential efficacy of this product. The Company’s long-term goal for its brain cancer treatment compound is to achieve approval from Health Canada and the US Food & Drug Administration.

JBR-102 - Cancer Treatment

JBR-102 is being developed as an oral therapeutic agent for patients with newly diagnosed, recurrent, or progressive glioblastoma multiforme (GBM), astrocytoma, and other neoplastic tumors. GBM, classified as a World Health Organization (WHO) grade IV astrocytoma, is one of the most aggressive and prevalent primary brain tumors in adults, characterized by rapid progression and poor prognosis. Despite advancements in treatment, effective therapeutic options remain limited, highlighting a significant unmet need for novel approaches to improve patient outcomes. The Company’s development of JBR-102 aims to address this gap by offering a potential new treatment option for GBM and other malignancies.

JBR-201 - Antiviral Treatment

The antiviral product is focused upon multiple sclerosis (MS) and SSPE. MS is characterized by acute exacerbations of neurological dysfunction with inter-current periods of improvement and quiescence. SSPE is a progressive, fatal disease of young children, directed at the Central Nervous System (CNS) caused by a persistent measles virus. JBR-201 is patented for treatment of Subacute Sclerosing Pan Encephalitis (SSPE) and Multiple Sclerosis (MS). Testing for antiviral activity against Epstein Barr, HIV and HPV (Human Papillomavirus) and a broad respiratory virus panel consisting of influenza, respiratory syncytial virus (RSV), adenovirus, parainfluenza virus, adenovirus, coronavirus (not the SARS-CoV2 type), rhinovirus, enterovirus, and human metapneumovirus is planned.